Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2020

View Archived Issues

Janpix describes small-molecule monovalent STAT3 and STAT5 protein degraders

CStone Pharmaceuticals presents data on the CDK4/6 inhibitor CS-3002

Phase II/III study begins with mavrilimumab in severe COVID-19 pneumonia and hyperinflammation

Bayer initiates first-in-human study of BAY-2701439 in advanced HER2-expressing cancers

M-6223 studied in first-in-human trial for metastatic or locally advanced solid unresectable tumors

Akeso begins phase II study of AK-104 in recurrent or metastatic cervical cancer

Fe-isty cancer cells flourish in hostile subarachnoid space

DS-6157a demonstrates promising efficacy in preclinical models of GIST

Novartis reports first-in-human data for BLZ-945

Regeneron reports preclinical data on 89Zr-labeled REGN-5054 antibody for CD8+ T-cell monitoring

Array BioPharma identifies new protein kinase inhibitors

Patient enrollment begins in Ampion COVID-19 program

In vivo studies show potent reversal of anticoagulation with VMX-COO1

Topline phase III data for favipiravir in patients with COVID-19

Promising preclinical data for NurOwn-derived exosome-based therapy for COVID-19 ARDS

Kaleido Biosciences initiates second study of KB-109 in outpatients with COVID-19

FDA lifts clinical hold on all development of seladelpar

Cybrexa Therapeutics details development of peptide-drug conjugate CBX-13 for solid tumors

Sareum reports findings with TYK2/JAK1 inhibitors in disease model of lupus

Exonbio launches SARS-CoV-2 monoclonal antibodies for research